Top Banner
Chapter 24 - Blood Therapy Seth Christian, MD MBA Tulane Anesthesiology
23

Chapter 24 - Blood Therapy

Jan 11, 2016

Download

Documents

TERENA

Chapter 24 - Blood Therapy. Seth Christian, MD MBA Tulane Anesthesiology. Overview of Perioperative Blood Transfusion and Adjuvant Therapies. Transfusion Medicine (T&S, T&C, Emergency transfusion, Storage) Transfusion Thresholds Blood Components (PRBC, Plt, FFP, Cryo) - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Chapter 24 - Blood Therapy

Chapter 24 - Blood Therapy

Seth Christian, MD MBATulane Anesthesiology

Page 2: Chapter 24 - Blood Therapy

Overview of Perioperative Blood

Transfusion and Adjuvant Therapies• Transfusion Medicine (T&S, T&C, Emergency transfusion, Storage)

• Transfusion Thresholds

• Blood Components (PRBC, Plt, FFP, Cryo)

• Complications and Risks

• Miscellaneous (autologous transfusion, cell-saver, normovolemic hemodilution)

Page 3: Chapter 24 - Blood Therapy

Practice Guidelines for Perioperative Blood Transfusions and Adjuvant Therapies

Page 4: Chapter 24 - Blood Therapy

Type and Screen• Type - the donor erythrocytes do not

have major antigens (A, B, Rh) that will react with antibodies in the recipient blood

• O negative blood - does not have any antigens, so it is the universal donor

• Screen - the donor erythrocytes do not have common antigens that will react with antibodies in the recipient blood

• T&S blood is recommended for procedures in which transfusion is unlikely, but possible (lap choly, TAH)

• Risk of Significant Transfusion Reaction = 1 in 10,000 units transfused

Page 5: Chapter 24 - Blood Therapy

Type and Cross• Cross-match - donor

erythrocytes are introduced to the recipient's plasma

• Major cross-match checks for IgG antibodies (Duffy, Kell, Kidd)

• T&C blood should be reserved for procedures in which transfusion is expected

• Risk of Significant Transfusion Reaction = 1 in 1,000 units transfused

Page 6: Chapter 24 - Blood Therapy

Emergency Transfusion

• It takes 5 minutes to perform a partial cross-match (donor erythrocytes introduced to recipient plasma, centrifuged and observed for agglutination

• Once 2 units of O-negative PRBC are transfused, subsequent transfusions should continue with O-negative blood

Page 7: Chapter 24 - Blood Therapy

Blood Storage• Temperature - 1 to 6 deg

C

• ADP (adenine, dextrose, phosphate)

• Adenine: fuel for ATP production/survival

• "Young blood" - < 14 days is associated with better outcomes.

Page 8: Chapter 24 - Blood Therapy

Decision to Transfuse

• BP, HR, UOP, O2, EKG, AGB, SvO2.

• Hgb <= 6 almost always require transfusion

• Hgb = 8 may be threshold for patients not at risk of ischemia

• Hgb = 10 may be threshold for patients at risk of ischemia (COPD, CAD, rapid bleeding).

• Hgb > 10 g/dl rarely require transfusion

Page 9: Chapter 24 - Blood Therapy

Decision to Transfuse

• Transfusion greater than 10 does not substantially increase O2 delivery

• "The exact Hgb value at which CO increases (compensatory) varies among individuals and is influenced by age, chronicity, and sometimes anesthesia"

Page 10: Chapter 24 - Blood Therapy

Decision to Transfuse

• Hypotension and tachycardia are likely, but may be blunted by anesthesia or other drugs

• Compensatory vasoconstriction may conceal the signs of acute blood loss until at least 10% of blood volume is lost

• Healthy patients may be able to lose 20% of blood volume before signs of hypovolemia occur.

Page 11: Chapter 24 - Blood Therapy

PRBCs• 250 - 300 ml with Hct

~70-80

• Cell Saver - Hct usually ~ 50

• Mix with NS (not hypotonic or LR)

• Ca++ may cause clotting

Page 12: Chapter 24 - Blood Therapy

Platelets• Probably not required unless

platelet count is less than 50,000

• Consider transfusing 1 pooled unit (6 pk) for every 6 units of PRBC in large transfusions

• Bacterial contamination is most likely to occur in platelet concentrates

• Platelet related sepsis incidence is as high as 1 in 5000 transfusions

• Desmopressin 20 mcg may be given for qualitative platelet disorders

Page 13: Chapter 24 - Blood Therapy

Fresh Frozen Plasma• All coagulation factors

except platelets

• Probably not necessary unless PT is > 1.5 times normal or INR > 2

• Warfarin reversal, heparin resistance

• FFP of 10-15ml/kg will achieve 30% of most plasma factor concentrations

Page 14: Chapter 24 - Blood Therapy

Cryoprecipitate• The fraction of plasma that

precipitates when FFP is thawed

• High concentrations of Factor VIII, fibrinogen

• Indicated for Hypofibrinogenemia and Hemophilia A

• Consider transfusion if fibrinogen less than 100 mg/dl

• Not recommended for patients with unstable coronary artery disease because ultralarge vWF multimers released by DDAVP can aggregate platelets and increase risk of infarction

Page 15: Chapter 24 - Blood Therapy

Complications• RIsk of fatal outcome due

to blood transfusion is remote but possible.

Page 16: Chapter 24 - Blood Therapy

Complications• Hyperthermia, increased airway pressures, and/or

change in urine output/color may be suggestive of transfusion reaction

• Febrile reaction: most common (0.5-1%) as a result of recipient antibodies to donor antigens on leukocytes or platelets

• Allergic reaction: also associated with pruritis and urticaria, bronchospasm

• Slow the infusion and give antipyretics for febrile reaction; give antihistamines, bronchodilators, and stop infusion for allergic reaction

Page 17: Chapter 24 - Blood Therapy

Complications• Hemolytic reactions: typically a

result of wrong blood type

• Lumbar and substernal pain, fever, chills, dyspnea, and skin flushing

• Free hemoglobin in plasma or urine, acute renal failure and DIC occur

• Discontinue transfusion and maintain urine output with IVF, mannitol and lasix

• Alkalinization of urine with bicarb and steroids are of unproven value

Page 18: Chapter 24 - Blood Therapy

Autologous Blood Transfusions

• Predeposited autologous donation (PAD):

• More expensive and not very effective at reducing allogenic blood transfusion

• Patients for elective surgery with high likelihood of transfusion may donate 10ml/kg of blood every 5-7 days if Hgb > 11g/dL up to a maximum of 3 units

Page 19: Chapter 24 - Blood Therapy

Autologous Blood Transfusion

• Infection or malignancy is a contraindication to blood intraop blood salvage (cell saver)

• Normovolemic hemodilution: early intraop donation and intravascular volume replacement with crystalloids to Hct of 27-33%

• Fewer RBC per millimeter of blood loss during surgery

Page 20: Chapter 24 - Blood Therapy

Complications• Incidence of infection from

blood transfusions has markedly decreased

• HCV transmission decreased from 1 in 10 to less than 1 in 1 million transfusions since 1980

• Nucleic acid technology responsible for improved viral testing

• HBV, HTLV, CMV, Malaria, Creutzfeldt-Jakob

Page 21: Chapter 24 - Blood Therapy

TRALI• Non-cardiac exudative

pulmonary edema in the absence of left atrial hypertension that occurs within 6 hours of transfusion

• Exclusion of female donors and fresher blood (< 14 days) decreases risk

• Stop transfusion, send off fluid from ETT, CBC, CXR, and notify blood bank so that other units may be quarantined

Page 22: Chapter 24 - Blood Therapy

Transfusion Related Immunomodulation

• Long-term prognosis in cancer surgery is unclear, but there is a suggestion of a correlation between tumor recurrence and blood transfusions

• Leukoreduction reduces incidence of nonhemolytic febrile transfusion reactions and transmission of leukocyte-associated viruses

• Leukoreduction to prevent cancer recurrence is more speculative

Page 23: Chapter 24 - Blood Therapy

Metabolic Abnormalities

• pH decreases, K increases, and 2,3-DPG decreases with duration of storage.

• Metabolic acidosis and hyperkalemia rarely occur even in massive transfusions

• Less 2,3-DPG increases affinity of Hgb for Oxygen, and potentially decreases tissue oxygen delivery

• Citrate metabolism to bicarbonate may contribute to metabolic alkalosis

• In anhepatic phase of liver transplant, citrate is not metabolized and it binds to calcium in blood causing hypocalcemia